Biocon Biologics partnered with international organisations to enhance access to life-saving cancer drugs for patients, especially in Sub-Saharan and Asian regions.
The Subject Expert Committee deliberated on the matter on 9 October and asked ICMR to submit 'clarifications and justifications' for inclusion of acalabrutinib in the trial.
The drug is a combination of ‘decitabine and cedazuridine’, which are used as agents for chemotherapy. But it may not be affordable for a large section of Indian patients.
India should have secured greater savings by pressing Russia for prices nearer the cap while sustaining high volumes. This would have preserved strategic autonomy and served economic logic.
One such website has drawn particular scrutiny for spreading fake stories that have upset not only the Indian but also foreign defence firms by falsely attributing misinformation.
COMMENTS